Processing Your Payment
Please do not leave this page until complete. This can take a few moments.
Research & Development
-
2023 Power 50: Bob Mumgaard
Updated: May 1, 2023Bob Mumgaard co-founded CFS in 2018 out of MIT with the goal of commercializing fusion energy, a puzzle whose solution has eluded scientists since the 1940s.
Updated: May 1, 2023
2023 Power 50: Stephen Woerner
Updated: May 1, 2023Stephen Woerner possesses the power to turn the lights on and off.
Updated: May 1, 2023
2023 Power 50: Parth Chakrabarti
Updated: May 1, 2023Parth Chakrabarti is responsible for growing the size, financials, and reach of the UMass Chan research enterprise.
Updated: May 1, 2023
2023 Power 50: Mike O’Kronley
Updated: May 1, 2023Under Mike O’Kronley’s leadership, Ascend closed $300 million in a funding round in 2022, and the company received more than $480 million grants from the U.S. Department of Energy, where O’Kronley participated in a press conference with President
Updated: May 1, 2023
2023 Power 50: Girish Navani
Updated: May 1, 2023In 1999, when Girish Navani co-founded eClinicalWorks, a healthcare software company hosting patient records, he had a background in robotics but a curiosity about health care and a desire to develop something to help patients and physicians alike.
Updated: May 1, 2023
2023 Power 50: Eugene Scherbakov
Updated: May 1, 2023Scherbakov has the distinction of being only the second person to lead the $1.4-billion IPG Photonics. In May 2021, he replaced its founder Valentin Gapontsev as the Marlborough company’s CEO.
Updated: May 1, 2023
Sunovion begins clinical trials for anxiety treatment
April 26, 2023Marlborough company Sunovion Pharmaceuticals Inc. has begun its in-human clinical trials for a drug to treat generalized anxiety disorder.
April 26, 2023
Cambridge startup wins UMass Chan, UMass Lowell seed funding contest
April 19, 2023Spheric Bio, a Cambridge company developing a 3D heart implant to help prevent strokes, was awarded $50,000 for winning the M2D2 Challenge, a partnership between UMass Chan Medical School and UMass Lowell.
April 19, 2023
Major operations: Large life science companies contribute mightily to the region
Updated: April 17, 2023Large for-profit life sciences companies have called Central Mass. their home for decades. Now, they play an important role in bringing talent, investment, and research to the region.
Updated: April 17, 2023
Diagnosing AI: Healthcare community excited, wary of artificial intelligence
Updated: April 17, 2023With the medical world on the cusp of an artificial intelligence revolution, researchers and clinicians are excited about the potential and wary of technology implicitly reliant on human bias
Updated: April 17, 2023
Bankrupting the system: High utilization of travel nurses still causing financial strain
Updated: April 17, 2023To cover for COVID-related staff shortages, hospitals are over-reliant on travel nurses, who are paid significantly more than staff.
Updated: April 17, 2023
Central Mass. life sciences research spans from alpacas to AI
Updated: April 17, 2023Researchers across Central Mass. are leading development of cutting-edge ideas and therapies to provide the next generation of solutions to present and future problems.
Updated: April 17, 2023
UMass Chan professor awarded $1M NSF grant for mRNA genomics research
April 12, 2023Athma Pai, assistant professor of RNA therapeutics at UMass Chan Medical School in Worcester, has received a $1-million CAREER grant from the National Science Foundation.
April 12, 2023
UMass Chan’s $358M leads record-breaking research year systemwide
April 12, 2023UMass Chan Medical School in Worcester had $358 million in research and development expenditures in fiscal 2022, leading the record-breaking $813-million year throughout the entire UMass system.
April 12, 2023
Framingham “Shark Tank” company rebrands industrial division
April 12, 2023DetraPel Inc. of Framingham has rebranded its industrial materials arm as Impermea Materials, which specializes in materials coating.
April 12, 2023
Biostage secures $6M to advance clinical trials
April 7, 2023Biostage, a cell-therapy biotech company based in Holliston, has received $6 million in commitments from investors to accelerate its clinical development program.
April 7, 2023
WBJ Web partners
Most Recent
